Cytokinetics, Incorporated (CYTK)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
82.24 USD
-2.63
(-3.099%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:16 a.m. EDT
Cytokinetics presents a classic biotech dilemma: robust momentum and analyst optimism clash with deteriorating profitability metrics. The stock has rallied nearly 267 percent over the last nine years, yet it currently burns cash at a rate of roughly 380 million dollars annually with negative operating margins. While the 11 percent revenue growth and strong liquidity cushion suggest the pipeline has value, the lack of earnings power keeps the long-term ceiling constrained compared to profitable peers. Short-term traders are positioned for volatility, with put writers protecting against dips while call buyers target upside, but the low-confidence statistical forecast warns that price action may be noisy. This is a high-conviction growth play for those comfortable with the risk of capitalization dilution, but not a stable income vehicle. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.184992 |
| MSTL | 0.204885 |
| AutoETS | 0.211509 |
| AutoARIMA | 0.211510 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.222 |
| Excess Kurtosis | 0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.872 |
| Market Cap | 11,165,772,800 |
| Forward P/E | -17.61 |
| Beta | 0.42 |
| Website | https://www.cytokinetics.com |
As of July 11, 2026, 4:16 a.m. EDT: Near-term expiration data shows higher implied volatility on protective puts, indicating a fear of downside correction. Longer-dated calls show significant open interest at lower strikes, suggesting investors are positioning for a recovery or a floor rather than a massive immediate spike. The volume imbalance suggests a defensive stance mixed with speculative upside bets.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1998444 |
| Address1 | 350 Oyster Point Boulevard |
| All Time High | 110.25 |
| All Time Low | 3.05 |
| Ask | 104.4 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 2,775,060 |
| Average Daily Volume3 Month | 2,620,509 |
| Average Volume | 2,620,509 |
| Average Volume10Days | 2,775,060 |
| Beta | 0.422 |
| Bid | 59.82 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | -6.653 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 82.24 |
| Current Ratio | 4.214 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 84.6 |
| Day Low | 80.9 |
| Earnings Call Timestamp End | 1,778,013,000 |
| Earnings Call Timestamp Start | 1,778,013,000 |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -629,041,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -17.262 |
| Enterprise To Revenue | 102.617 |
| Enterprise Value | 10,858,406,912 |
| Eps Current Year | -6.32213 |
| Eps Forward | -4.67047 |
| Eps Trailing Twelve Months | -6.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 76.1896 |
| Fifty Day Average Change | 6.0504 |
| Fifty Day Average Change Percent | 0.079412416 |
| Fifty Two Week Change Percent | 119.984436 |
| Fifty Two Week High | 88.31 |
| Fifty Two Week High Change | -6.0699997 |
| Fifty Two Week High Change Percent | -0.06873514 |
| Fifty Two Week Low | 32.89 |
| Fifty Two Week Low Change | 49.35 |
| Fifty Two Week Low Change Percent | 1.5004561 |
| Fifty Two Week Range | 32.89 - 88.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,083,331,800,000 |
| Float Shares | 123,870,130 |
| Forward Eps | -4.67047 |
| Forward P E | -17.608505 |
| Free Cashflow | -381,057,760 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 673 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -2.90728 |
| Gross Profits | -307,633,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00672 |
| Held Percent Institutions | 1.18786 |
| Implied Shares Outstanding | 135,770,593 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=142156&p=irol-IRHome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,372,118,400 |
| Last Split Factor | 1:6 |
| Long Business Summary | Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. |
| Long Name | Cytokinetics, Incorporated |
| Market | us_market |
| Market Cap | 11,165,772,800 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_27315 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -829,609,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,522,850,227 |
| Number Of Analyst Opinions | 20 |
| Open | 83.42 |
| Operating Cashflow | -523,848,992 |
| Operating Margins | -9.48685 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 650 624 3000 |
| Pre Market Change | -0.23999786 |
| Pre Market Change Percent | -0.29182622 |
| Pre Market Price | 82.0 |
| Pre Market Time | 1,784,026,942 |
| Previous Close | 84.87 |
| Price Eps Current Year | -13.008273 |
| Price Hint | 2 |
| Price To Book | -12.3613405 |
| Price To Sales Trailing12 Months | 105.521645 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.144 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -2.63 |
| Regular Market Change Percent | -3.09886 |
| Regular Market Day High | 84.6 |
| Regular Market Day Low | 80.9 |
| Regular Market Day Range | 80.9 - 84.6 |
| Regular Market Open | 83.42 |
| Regular Market Previous Close | 84.87 |
| Regular Market Price | 82.24 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,868,856 |
| Return On Assets | -0.31539 |
| Revenue Growth | 11.258 |
| Revenue Per Share | 0.872 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 135,770,593 |
| Shares Percent Shares Out | 0.1294 |
| Shares Short | 17,573,660 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 15,500,865 |
| Short Name | Cytokinetics, Incorporated |
| Short Percent Of Float | 0.2001 |
| Short Ratio | 7.16 |
| Source Interval | 15 |
| State | CA |
| Symbol | CYTK |
| Target High Price | 146.0 |
| Target Low Price | 83.0 |
| Target Mean Price | 107.8 |
| Target Median Price | 105.0 |
| Total Cash | 818,550,016 |
| Total Cash Per Share | 6.578 |
| Total Debt | 1,443,623,040 |
| Total Revenue | 105,815,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 66.06245 |
| Two Hundred Day Average Change | 16.177551 |
| Two Hundred Day Average Change Percent | 0.24488272 |
| Type Disp | Equity |
| Volume | 1,868,856 |
| Website | https://www.cytokinetics.com |
| Zip | 94,080 |